Constipation in Medical Technology

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

... 419 patients with irritable bowel syndrome with constipation (IBS-C). Previous analyses of these data ... of linaclotide in patients with IBS-C or chronic constipation (CC). (Logo: ... About Irritable Bowel Syndrome with constipation (IBS-C) IBS-C is a chronic functional ...

Ironwood Announces Linaclotide European Licensing Agreement with Almirall

... the treatment of irritable bowel syndrome with constipation (IBS-C) and other gastrointestinal conditions. ... for the treatment of IBS-C and chronic constipation (CC). Linaclotide demonstrated proof of concept ... period. In patients with CC, linaclotide reduced constipation throughout the 4-week treatment period. In both ...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

... study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-118, a peripheral opioid antagonist, ... which the patient had to demonstrate significant constipation in the absence of laxatives, to the change in ... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome and is generally ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the following important adverse ... <1%, 2%; anorexia 1%, 1%; headache 2%, 4%; constipation 1%, 0%; convulsions 3%, 3%; thrombocytopenia 3%, ... 6%, 42%; headache 6%, 41%; fatigue 4%, 34%; constipation 1%, 33%; convulsions 5%, 23%; with the following ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... The most common treatment-emergent AEs were constipation (64 percent), fatigue (60 percent) and nausea (52 ... weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including ... 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%) and vomiting (21%). The ... (>10%) were rash (28%), pruritus (20%) and constipation (18%). The most common (>10%) Grade 3/4 ... anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness ...

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

... 420 patients with irritable bowel syndrome with constipation (IBS-C). Analysis of the data indicates that ... study showing improvement in abdominal pain and constipation are encouraging," said Douglas Drossman, M.D., ... patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer ...

Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3

... the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), to invest in a growing pipeline of ... linaclotide reduced abdominal pain and relieved constipation -- the hallmarks of the condition -- throughout ...

Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference

... 419 patients with irritable bowel syndrome with constipation (IBS-C) in a plenary session at the American ... for its potential to treat IBS-C, chronic constipation (CC), and other gastrointestinal disorders. ... patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer ...

New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study

... therapy for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are ... to manage their pain, and experts say that constipation occurs in practically all of them. However, for ... United States for the treatment of opioid-induced constipation in patients with advanced illness who ...

Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results

... none of the placebo-treated patients. "Chronic constipation is an uncomfortable condition that can ... with CC and irritable bowel syndrome with constipation (IBS-C). Ironwood and Forest previously announced ... and bloating on a daily basis, and constipation severity and overall relief ...

New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)

... overall symptoms of Irritable Bowel Syndrome with constipation (IBS-C). These results were presented at ... mcg dose for the treatment of Chronic Idiopathic constipation in adults. These data were among others presented ... About Irritable Bowel Syndrome with constipation (IBS-C) IBS is a disorder characterized by ...

New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR

... nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead ... lower incidence of nausea, vomiting, constipation and composite nausea/vomiting (P<0.001) for all ... While the incidence of nausea, vomiting, constipation and the composite nausea and vomiting were ...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome, and is ... opioids are likely to experience significant constipation and other symptoms of OBD. According to ... for moderate-to-severe pain revealed that constipation is one of the most common opioid-related side ...

Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies

... - Chronic constipation and IBS-C studies each meet primary endpoint - ... effects of linaclotide in patients with chronic constipation (CC), while the second study examined its effects ... and constipation severity and overall relief of constipation on a weekly basis. In addition, the use of rescue ...

Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies

... is extremely successful at relieving symptoms of constipation and Irritable Bowel Syndrome. In fact, the ... standard for patients seeking relief for their constipation and IBS symptoms. Dr. Edward Group III, the ... to help millions of people suffering from constipation and IBS symptoms, he added, "The results were ...

Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction

... treatment being developed to treat opioid-induced constipation (OIC) and other clinical manifestations ... tolerability of NKTR-118 in patients experiencing constipation while receiving opioid therapy. "We are excited ... target peripheral opioid receptors to alleviate constipation associated with opioid therapy, while reducing ...

Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting

... dysfunction (OBD), including opioid-induced constipation (OIC). Data from a single-dose, ... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome, and is ... opioids are likely to experience significant constipation and other symptoms of OBD. Currently, there are ...

Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)

... approved for the treatment of Chronic Idiopathic constipation in adults as AMITIZA(R) (24 mcg, oral gel ... lubiprostone can help many Americans who have constipation as a result of taking opioid-based drugs for ... conditions inclusive of severe constipation brought about by the use of narcotic medications ...

New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression

... include: -- For MDD: Nausea, dry mouth and constipation -- For DPNP: Nausea, somnolence (sleepiness), dizziness and constipation -- For GAD: Nausea, fatigue, dry mouth, somnolence (sleepiness) and constipation This is not a complete list of side effects. ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( > 10%) ... adverse reactions ( > 10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( > 10%) Grade 3/4 adverse reactions were ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ...

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

... side effects that occurred greater than placebo (a "sugar" pill) were constipation (11.0% vs. 7.0%), indigestion (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), ... with type 2 diabetes side effects that occurred greater than placebo were constipation (8.7% vs. 2.0%), inflamed nasal passages and throat (4.1% vs. 3.6%), ...

Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain

... compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to ... treat the nine million U.S. patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer from CC. Patients with CC ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ...

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations

... bromide) for the treatment of opioid-induced side effects, including constipation (subcutaneous and oral formulations) and post-operative ileus (intravenous ... subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, ...

Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome

... trial, approximately 33 percent were characterized as D-IBS, 37 percent constipation predominant (C-IBS) and 31 percent alternating between diarrhea and constipation (A-IBS). -- In the overall patient group, patients with at least ...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

... The most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity ... pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit http://www.mgipharma.com or ...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

... rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( >10%) Grade ... reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( >10%) Grade 3/4 adverse reactions were ...

Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials

... for the treatment of opioid-induced side effects, including constipation (oral and subcutaneous formulations) and post-operative ileus (intravenous ... formulation of methylnaltrexone for patients suffering from opioid-induced constipation while receiving palliative care, followed in May 2007 by Wyeth's ...

AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression

... were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia (10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural hypotension (7% vs 2%), ... placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral neuropathy ... events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite ...

SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia

... were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia (10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural hypotension (7% vs 2%), ... placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... fatigue (80%); thrombosis/embolism (7%); nausea (84%); vomiting (58%); constipation (44%); anorexia (35%); stomatitis/pharyngitis (28%); diarrhea (26%); ... events (all grades) were fatigue (87%); anorexia (62%); nausea (39%); constipation (30%); vomiting (25%); diarrhea (21%); stomatitis/pharyngitis (20%); ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in ... (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%). About ImClone Systems ImClone Systems ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC). NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated ...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

... (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 percent), petechiae (39 percent), constipation (35 percent), and diarrhea (34 percent). Please visit www.dacogen.com for full prescribing information. About Eisai Corporation of ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... frequency greater than or equal to 10% among lurasidone subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... 2 clinical studies. Carfilzomib was generally well tolerated. The most common adverse events include fatigue headache, nausea, diarrhea, constipation and anemia. Notably, there were no incidents of Grade 3/4 neuropathy, a common side effect associated with the approved proteasome inhibitor, ...